Visium Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Visium Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-15,833	Closed	-$10M	–	1222
2015 Q2	$10M	Buy	15,833 +1,547	+11%	+$822K	0.14%	155
2015 Q1	$7.35M	Buy	14,286 +7,008	+96%	+$3.54M	0.11%	192
2014 Q4	$3.9M	Sell	7,278 -12,217	-63%	-$5.5M	0.06%	304
2014 Q3	$29.2M	Sell	19,495 -2,061	-10%	-$2.98M	0.43%	39
2014 Q2	$29.5M	Hold	21,556	–	–	0.46%	37
2014 Q1	$29.9M	Buy	21,556 +1,906	+10%	+$2.22M	0.48%	41
2013 Q4	$19.6M	Sell	19,650 -6	-0%	-$6.2K	0.38%	55
2013 Q3	$20.5M	Buy	19,656 +260	+1%	+$278K	0.46%	51
2013 Q2	$21.2M	Buy	+19,396	New	+$21.6M	0.5%	42

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Visium Asset Management's VIRX Position: Q3 2015 in Review

Visium Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 15,833 shares — an estimated $10M sold.

Visium Asset Management first reported a position in VIRX in Q2 2013 and held it in 9 quarters. The position peaked at $29.9M in Q1 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

Visium Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
Visium Asset Management sold 15,833 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $10M.
Visium Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
Visium Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $29.9M in Q1 2014.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.